The mortality rate due to colorectal cancer is second only to lung cancer. One of the strategies to reduce human cancer is by chemoprevention. While there are a number of chemical compounds that show great promise as potential chemopreventive agents, more specific inhibitors of colon carcinogenesis remained to be discovered and tested. This research project proposes to develop a rapid in vivo screening assay that will be useful to test a large number of chemicals as potential inhibitors of colon cancer. In this phase I project, the optimum condition for the assay will be determined using strains of animals that are known to produce colon tumors. Early preneoplastic lesions will be induced in the colon mucosa by colon carcinogens. The inhibition of these early lesions by inhibitors of carcinogenesis will be determined within three weeks. The total experimental period for this assay will be less than four weeks. Because of the short duration required for this assay, large numbers of compounds may be screened with much less expense than in vivo animal tumor models. Since the lesions produced are preneoplastic in nature that will eventually advance to cancerous state, this technique may also be applicable as a screening assay for colon carcinogens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA054037-01A1
Application #
3492758
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1991-09-10
Project End
1992-07-31
Budget Start
1991-09-10
Budget End
1992-07-31
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Lkt Laboratories, Inc.
Department
Type
DUNS #
City
St. Paul
State
MN
Country
United States
Zip Code
55114